Equity Details
Price & Market Data
Price: $1.10
Daily Change: $0.00 / 0.00%
Daily Range: $1.10 - $1.41
Market Cap: $2,944,300
Daily Volume: 416
Performance Metrics
1 Week: 10.00%
1 Month: -6.78%
3 Months: -14.73%
6 Months: 57.17%
1 Year: 12.24%
YTD: -8.33%
About Vaccinex, Inc. (VCNX)
Dive deep into Vaccinex, Inc. (VCNX)'s market performance. Current price: 1.10, daily change: $0.00 / 0.00%. Market cap: 2,944,300. All key performance metrics are available, from 1-week to 1-year and YTD.
Company Details
Employees: 27
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer. The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses. In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.